在马来西亚对人类表皮生长因子受体2 (HER2) 低水平的乳腺癌检测的共识指南
Pathmanathan Rajadurai1,2,3, Sarala Ravindran4, Bang Rom Lee5
1Subang Jaya Medical Centre, Subang Jaya 47500, Malaysia.
Cancers
|July 13, 2024
概括
本指南针对马来西亚的低HER2乳腺癌检测. 它为病理学家提供建议,以确保HER2-低乳腺癌患者的准确诊断和治疗.
科学领域:
- 在瘤学瘤学.
- 病理学 病理学 病理学
背景情况:
- 乳腺癌是马来西亚的主要癌症.
- 一个新的分类定义了HER2-低乳腺癌 (HER2 IHC 1+或2+/ISH-负).
- 低HER2乳腺癌受益于向的抗HER2疗法.
更多相关视频
11:34Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
12.6K
08:29Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
95
